Down regulation of the ING1 candidate tumour suppressor promotes growth in soft agar and focus formation in vitro and tumour formation in vivo. ING1 encodes a nuclear, cell cycle-regulated protein, overexpression of which eciently blocks cell growth and is capable of inducing apoptosis in dierent experimental systems. Here we present the ®rst report of ING1 mutation and expression analysis in a total of 452 cancer samples. One germline missense alteration and three germline silent alterations were detected in 377 primary breast cancers while marked (2 ± 10-fold) decreases in ING1 mRNA expression were seen in 44% of primary breast cancers and in ten of ten breast cancer cell lines examined. Furthermore, the majority of breast cancers (58%) showing decreased ING1 expression had metastasized to regional lymph nodes whereas only 9% of cancers with elevated ING1 expression, compared to adjacent normal tissues, were metastatic. Thus, ING1 mutation is very rare in breast or ovarian cancers, however, repression of ING1 expression frequently accompanies tumour development of breast cancer.
Introduction
Tumour suppressor genes play important roles in the regulation of cell growth and dierentiation. Characterization of various human cancers on the basis of molecular genetics has indicated involvement of altered tumour suppressor genes in the genesis and progression of carcinoma (Devilee, 1994) . We have recently cloned a novel growth inhibitor and candidate tumour suppressor gene called ING1 using a method that combined PCR-mediated subtractive hybridization of cDNAs (Lisitsyn et al., 1993) from normal and cancerous cells with adaptor-mediated enrichment (Diatchenko et al., 1996) and an in vivo selection assay (Garkavtsev et al., 1996) . The ING1 gene localized to chromosome 13q33 ± 34 (Garkavtsev et al., 1997b) , a site that has been implicated in the progression of various tumours (Maestro et al., 1996; Motomura et al., 1988; Mostert et al., 1996; YangFeng et al., 1992) . It also appears to have a role in programmed cell death as its expression confers sensitivity to apoptosis whereas antisense ING1 protects cells from apoptosis in dierent experimental systems (Helbing et al., 1997) . Expression of ING1 is also regulated through the cell cycle and its growth inhibitory eects are abrogated by SV40 large T antigen .
Recently, ING1 protein (p33 ING1 ) has been reported to cooperate directly with p53 in growth regulation by modulating the ability of p53 to act as a transcriptional activator (Garkavtsev et al., 1998) . The biological eects of increasing and decreasing ING1 expression and the involvement of p33
ING1 in the p53 signalling pathway indicate that ING1 may be a tumour suppressor, and that functional loss of ING1 might contribute to tumorigenesis.
BRCA1 and BRCA2 contribute to a signi®cant fraction of familial breast and ovarian cancers, and breast cancers, respectively. However, they undergo mutation at very low rates in sporadic breast and ovarian cancers which suggests that functional inactivation of additional genes also contributes to the genesis and development of these cancer types. To test this idea, we have examined both the mutational status and expression levels of ING1 in primary human breast and ovarian cancers.
Results
Infrequent alterations of the ING1 gene in primary breast and ovarian cancers, and breast cancer cell lines
Since there is some indication that dierent factors predispose towards breast cancer in dierent populations, we have examined the mutational status of ING1 in a number of tumours, initially screening for mutation in 240 primary breast cancer tissues from Japanese patients, 137 from Canadian patients, ten breast cancer cell lines of various origin, and 65 primary ovarian cancer tissues using PCR ± SSCP analysis. DNA sequence was determined for any PCR product that showed a variant pattern by SSCP analysis, and DNA from corresponding normal lymphocytes was also examined to determine whether this variant was a somatic or germline alteration. One germline missense alteration and three germline silent alterations were detected in primary breast cancers (Table 1) . The tumour DNA from the missense alteration case had a C-to-T transition at the ®rst nucleotide of codon 95, which results in a Proline to Serine substitution (Figure 1 ). This alteration was also present in the corresponding normal lymphocyte DNA from this patient indicating that this alteration was germline. The age of cancer onset for this patient was 38 years, and the tumour was aggressive, being classi®ed as clinical stage III (Japanese Breast Cancer Society, 1992) . Elevated levels of mutant p53 were not detected immunohistochemically, c-erbB-2 and int-2 expression showed no ampli®cation by Southern blot analysis, however, the expression of RB was very low in this tumour and c-myc was also ampli®ed (Yamashita et al., 1993) . No family history of cancers was evident.
Eighteen of 240 Japanese breast cancer patients (7.5%) had a G-to-A substitution at the third nucleotide of codon 188, which represented a serine to serine silent germline alteration (Table 1) . Interestingly, we could not detect this alteration in (a) ING1 mRNA expression levels in tumour (T) and in matched adjacent normal mammary (N) tissues were monitored by`primer dropping' RT ± PCR which includes internal controls (GAPDH) for RNA integrity, RT and ampli®cation eciency in every sample (Wong et al., 1994) . Canadian patients. Other silent germline alterations were a G-to-A substitution at the third nucleotide of codon 166 (arginine to arginine) and a T-to-C substitution at the third nucleotide of codon 228 (cysteine to cysteine). These alterations were also detected in Japanese patients only. No alterations were detected in breast cancer cell lines and in the 65 ovarian cancer tissues examined.
Decreased levels of ING1 mRNA are frequently seen in breast cancer cell lines and in primary breast cancers
The expression levels of ING1 mRNA were examined in 48 randomly selected paired samples of primary breast cancer tissues and matched adjacent normal breast tissues from the NCIC Manitoba Breast Tumour Bank, and in ten breast cancer cell lines by RT ± PCR. PCR primers were designed to span an intron sequence in order to eliminate the potential contribution of genomic DNA. Our results show that ING1 mRNA expression was decreased (2 ± 10-fold) in 44% (21/ 48) of breast cancer tissues compared to adjacent normal tissues while 33% (16/48) of tumours showed levels similar to control sample and 23% (11/48) showed increases in ING1 mRNA (Figure 2a) . Recently, additional splicing variants of ING1 have been identi®ed by our and other groups (in preparation). We therefore designed another two sets of primers including one to amplify a commonly expressed splicing variant we call ING1-B (GenBank accession AF044076) and one that ampli®es within a single exon conserved in all known splicing variants. Results from RT ± PCR of ING1-B show that approximately 80% (37/48) of paired breast samples show results that parallel those found for ING1 while the remaining samples show slight variations. Results using primers to amplify total ING1 transcripts also show very similar results (Figure 2b ) indicating that in breast tissue, the dierent variants of ING1 are expressed coordinately in the great majority of samples.
Examination of the relationship between ING1 mRNA expression levels and clinicopathologic factors of breast cancer samples indicated that a signi®cant correlation between expression levels and the probability of metastasis to regional lymph nodes existed (Table 2 ). Only one of 11 tumours (9%) showing increased ING1 mRNA expression had metastasized to lymph nodes whereas 11 of 19 cases (58%) showing decreased expression of ING1 exhibited metastasis to lymph nodes (increased cases vs decreased cases: P=0.0182). No signi®cant associations between ING1 mRNA expression levels and other clinicopathologic features were observed (Table 2) .
Decreased levels of ING1 mRNA are also observed in breast cancer tissues using in situ hybridization
To con®rm by an independent method that ING1 mRNA expression decreased in advanced breast cancers compared to early stage cancers and normal tissues, we performed non-radioisotopic in situ hybridization on breast cancer samples. As shown in Figure 3a ± f, ING1 mRNA levels are clearly decreased in breast cancer cells relative to adjacent normal mammary epithelial cells. Decreased levels of ING1 mRNA expression were also observed in invasive components of breast cancer compared to DCIS as illustrated in a separate experiment shown in Figure 3g and h.
Levels of ING1 mRNA re¯ect protein levels
We examined both ING1 protein and mRNA expression in ten independent samples derived from breast cancer cell lines by Western blotting analysis and RT ± PCR, respectively. As shown in Figure 4a , Figure  4b , our data shows that the relative levels of polypeptide recognized by an ING1 monoclonal antibody (Garkavtsev et al., 1997a) in these samples are very similar to the relative levels of mRNA seen in the majority of samples (compare the pattern of bar graphs in Figure 4a,b) .
Discussion
This study has established several facts about the ING1 candidate tumour suppressor. First, the ING1 gene is mutated very rarely in primary breast or ovarian cancers and breast cancer cell lines. Second, expression of the gene is reduced in a high proportion of breast tumours (44%) and in all breast cancer cell lines examined. Third, ING1 protein levels parallel the levels of mRNA seen in most breast cancer cells. Fourth, ING1 expression levels correlate strongly with metastasis, with primary tumours showing reduced levels of ING1 being metastatic at a frequency at least sixfold greater than these showing increased levels of ING1 (57% vs 9%, respectively).
We screened for mutation of the ING1 gene in 377 primary breast cancer tissues, ten breast cancer cell lines and 65 primary ovarian cancer tissues. One germline missense and three germline silent alterations were detected in primary breast cancers. A germline missense alteration showed a C-to-A transition resulting in a proline to serine substitution. This change would be predicted to have severe eects upon protein conformation making it more likely that this is a germline mutation rather than a very rare polymorphism. However, we cannot exclude the possibility that this nucleotide change is a polymorphism because the biological eect caused by this alteration has not yet been determined. Although we examined a total of 442 breast or ovarian cancer tissues and ten breast cancer cell lines and the resulting data suggest that ING1 alterations occur with very low frequency, this is a minimal estimate. PCR ± SSCP analysis is reported to be less than 100% sensitive for mutation detection (VidalPuig and Moller, 1994) and ING1 has two splicing variants which have one large conserved common exon. The common exon accounts for approximately 75 and 85% of coding region for ING1 and ING1-B, respectively. In this study, primers for PCR ± SSCP analysis were designed within the common exon, therefore our data likely underestimates the contribution of ING1 mutations to the overall incidence of breast and ovarian cancers. Determination of the genetic structure of the ING1 gene and analysis of the entire coding region is presently being undertaken and will help to re®ne our estimates of mutation rate.
Although the mutation rate is very low, the frequency of down regulation of ING1 in tumours is very substantial, similar to those described for BRCA1 (Thompson et al., 1995; Dobrovic and Simpfendorfer, 1997; Magdinier et al., 1998; Rice et al., 1998; Sourvinos and Spandidos, 1998) Furthermore, down regulation of ING1 was observed in all breast cancer cell lines examined (ten of ten). Using in situ hybridization, down regulation of ING1 mRNA was also observed in breast cancer cells while normal mammary epithelial cells expressed ING1 mRNA at higher levels, and lower levels of ING1 were observed in invasive components of breast cancer compared to DCIS (Figure 3 ) in the majority of samples analysed. These data suggest that down regulation of ING1 expression accompanies, and may contribute to the process of cancer development.
From analysis of the mRNA expression levels of the ING1 gene, we noted an interesting correlation between the level of ING1 expression and aggressiveness of the tumour as judged by whether the tumour had metastasized. Although we have no evidence that ING1 plays a role in metastasis per se, observations have been made linking BRCA1 levels to neoplastic progression. For example, BRCA1 mRNA is expressed at several-fold higher levels in normal mammary tissues than in invasive breast cancer tissues, although higher levels of BRCA1 mRNA expression were observed in DCIS samples than in normal mammary tissues (Thompson et al., 1995) . While the explanation of the ®nding that expression levels of BRCA1 are increased in DCIS is unclear, one possibility is that normally functioning BRCA1 may be an active inhibitor of neoplastic progression in breast epithelial cells and the increased expression of BRCA1 in DCIS could be a response to genetic alterations that predispose to develop invasive breast cancer. Our data for ING1 expression are similar to those reported for BRCA1 expression (Thompson et al., 1995) . We observed that expression levels of ING1 are increased in some breast cancers, and that 91% (10/11) of them showed no lymph node metastasis. If the above-mentioned hypothesis regarding BRCA1 is accurate, ING1 in these breast cancers also could be responsive to genetic alterations that predispose to develop more advanced breast cancer.
We have shown previously in dierent human cell types that the levels of ING1 mRNA are a good predictor of protein levels . However, since tumour cells can show uncoupling of mRNA and protein levels for dierent genes, we examined both ING1 protein and mRNA expression in ten breast cancer cell lines. Our data shows that the relative levels of ING1 protein expression in these samples are very similar to the relative levels of ING1 mRNA seen in the majority of cell lines corroborating earlier observations that ING1 protein levels are regulated primarily at the level of transcription .
The mechanism by which ING1 inhibits growth and possibly contributes to breast cancer progression through reduced expression is presently unknown, however p33
ING1 has recently been reported to be essential for p53 function (Garkavtsev et al., 1998 ). ING1 appears to be able to also exert cellular eects independently of p53 since a role in apoptosis was observed in the absence of transcriptionally active p53 (Helbing et al., 1997) . Thus, decreased expression of ING1 mRNA in breast cancers may contribute to both altered cell growth control through involvement of p33 ING1 in the p53 signalling pathway and to resistance to apoptosis by p53-independent mechanisms.
Materials and methods

Tumour tissues and cell lines
Tumour tissues and matched normal lymphocytes or adjacent normal mammary tissues were obtained from Nagoya City University Hospital, the University of Saskatchewan Hospital, Calgary Foothills Hospital, and from the Manitoba Breast Tumour Bank. Breast cancer cell lines (BT-20, BT-474, MCF-7, SK-BR-3, BT-483, MDA-MB-435S, MDA-MB-468, T-47D, Hs 578T, ZR 75-1) were grown in Dulbecco's modi®ed Eagle's medium with 10% FBS or in RPMI 1640 with 10% FBS in 5% CO 2 , and were harvested for RNA, DNA or protein by standard methods.
DNA and RNA extractions
For DNA extraction, samples were homogenized and suspended in STE buer (100 mM Tris-HCl (pH 8.0), 10 mM NaCl, 1 mM EDTA (pH 8.0)) with 50 mg/ml proteinase K and 0.1% SDS at 508C for 3 ± 4 h. Genomic DNA was extracted using the phenol-chloroform method. Total RNA was isolated by Trizol reagent (Life Technologies, Inc., Burlington, Canada) according to the manufacturer's recommendations.
RT ± PCR
ING1 mRNA expression in tumours and in normal tissues was monitored by duplex RT ± PCR (Wong et al., 1994) . Each 20 ml cDNA synthesis reaction contained 1 mg of total RNA from tumour and normal cells, buer (10 mM Tris-HCl (pH 9.0), 50 mM KCl, 1.5 mM MgCl 2 ), 1 mM each of deoxynucleoside triphosphates, 25 units of RNAguard RNase inhibitor (Pharmacia Biotech Inc., Baie dU'rfeÂ , Canada), 200 units of Superscript II reverse transcriptase (Life Technologies, Inc.), and 100 ng of pd(N) 6 random hexamer (Pharmacia). One ml of each RT reaction was ampli®ed using 1 unit of Taq DNA polymerase (Pharmacia). Thirty-three PCR cycles for ING1 (forward intron-spanning primer: 5'-CCGCATCTTTGCTGACCCGA-3', reverse intron-spanning primer: 5'-GCCTTCTTCTTCTTGGGTGT-3'; forward conserved exon primer: 5'-CTGAAGGAGCTA-GACGAGTG-3', reverse conserved exon primer: 5-'-ACG-CACGAGAAGTGGAACCA-3') and for ING1-B (forward intron-spanning primer: 5'-CTCCATCGAGTCCCTGCCTT-3', reverse intron-spanning primer: 5'-GCCTTCTTCTT-CTTGGGTGT-3'), and 22 PCR cycles for GAPDH (forward primer: 5'-CGGAGTCAACGGATTTGGTCG-TAT-3', reverse primer: 5'-AGCCTTCTCCATGGTGGT-GAAGAC-3') were used for ampli®cation consisting of 1 min at 948C, 1 min at 628C, 1 min at 728C, with a 5 min extension at 728C following the last cycle. Primers for GAPDH were added to PCR tubes at the end of the 11th cycle. Before RT reactions, RNase-free DNase I (Life Technologies, Inc.) was used to remove DNA contamination for conserved exon primers according to the manufacturer's instructions. Reproducibility was con®rmed by processing all samples at least twice.
PCR ± SSCP analysis
PCR reactions were carried out in a volume of 50 ml containing 200 ng of genomic DNA, 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl (pH 9.0), 0.2 mM of each deoxynucleoside triphosphates, 0.5 mM of each primer, and 1 unit Taq DNA polymerase. Thirty cycles were used for ampli®cation consisting of 1 min at 948C, 1 min at 608C, 1 min at 728C, with a 5 min extension at 728C following the last cycle with visualization by a non-radioisotopic method as described (Iwase et al., 1996) . Gels were electrophoresed for 1.5 ± 4 h at 600 V, and were stained with ethidium bromide (1.0 mg/ml) for 10 min. The sequences of ING1 primer pairs used for PCR ± SSCP analysis were: primer set I (forward primer: 5'-CTGAAGGAGCTAGACGAGTG-3' (nucleotides 201-221 (Garkavtsev et al., 1996) ), reverse primer: 5'-GGCTTGTCA-GACTGCGCTAC-3' (nucleotides 474 ± 494)), primer set II (forward primer: 5'-GTAGCGCAGTCTGACAAGCC-3' (nucleotides 474 ± 494), reverse primer: 5'-ACGCACGA-GAAGTGGAACCA-3' (nucleotides 763 ± 783)), primer set III (forward primer: 5'-GACAACGACGAGTGCCCCAT-3' (nucleotides 739 ± 759), reverse primer: 5'-CTACCTGTTG-TAAGCCCTCTCT-3' (nucleotides 879 ± 901)). Analysis of all samples showing bands of dierent mobilities was repeated two to four times to ensure reproducibility.
Direct sequencing of PCR products
Abnormal bands detected by PCR ± SSCP analysis were cut out of gels, reampli®ed by PCR and puri®ed using Geneclean II Kits (BIO 101 Inc., Vista, CA, USA). Sequencing was done using a model 373A, version 1.2.0 genetic analyser by the Southern Alberta DNA Synthesis and Sequence Facility.
In situ hybridization
A 987 bp EcoRI ± XhoI fragment of ING1 in plasmid pBS was used to generate antisense riboprobe with T3 RNA polymerase from template linearized with EcoRI, and sense riboprobe with T7 RNA polymerase and XhoI-digested plasmid. In situ hybridization was performed as described previously (Harvey et al., 1995; Leco et al., 1997) . Brie¯y, eight micrometer paran-embedded breast cancer sections were dewaxed in xylene and rehydrated through a series of graded ethanol solutions. Sections were treated with proteinase K (20 mg/ml), acetylated, prehybridized, and hybridized overnight with digoxigenin-labelled probes. Hybridization was followed by RNase A treatment and four stringent washes. After this procedure, we performed two dierent methods as follows; (I) (Figure 3a ± f): sections were incubated in 1% hydrogen peroxide to block endogenous peroxidase. To reduce nonspeci®c binding, they were incubated in 4% normal goat serum, and then incubated in mouse monoclonal antibody against digoxigenin (Boehringer Mannheim, Laval, Canada) overnight at 4%. Goat antimouse horseradish peroxidase (Pierce, Rockford, IL, USA) was used as secondary antibody. Brown colour of peroxidase was developed in DAB (Sigma, Oakville, Canada), enhanced in 0.5% copper sulphate and hematoxylin was employed as a nuclear counter stain. Sections were dehydrated and mounted in Flo-Texx mounting media (Lerner Laboratories, Pittsburgh, PA, USA) and photographed under bright ®eld illumination. (II) (Figure 3g and h): sections were incubated in a 1 : 500 dilution of sheep anti-digoxigenin-alkaline phosphatase-conjugated antibody (Boehringer Mannheim) overnight. Subsequently, NBT/BCIP (Boehringer Mannheim) was added and sections were incubated in the dark. The reactions were terminated by placing sections in 10 mM Tris-HCl (pH 8.0)/10 mM EDTA (pH 8.0). After extensive washing, sections were mounted in Kaiser's mounting medium (7.7% gelatin, 54% glycerol and 0.2% phenol) and photographed under bright ®eld illumination.
Western blotting
Breast cancer cells growing in 10 cm tissue culture dishes (approximately 3610 6 cells per dish) were washed with icecold PBS, dissolved in sample buer, and sonicated. Two sets of proteins were separated by electrophoresis through 15% SDS-polyacrylamide gels, and were stained with Coomassie brilliant blue (Bio-Rad Laboratories, Hercules, CA, USA) or transferred to PolyScreen microporous polyvinylidene diuoride membranes (NEN Life Science Products, Boston, MA, USA) for 2 h at 20 V. Membranes were blocked in PBS with 5% nonfat dried milk and 0.1% Tween-20 overnight.
Blocked membranes were incubated with an undiluted mouse p33 ING1 monoclonal antibody hybridoma supernatant or with a 1 : 1000 dilution of rabbit p33
ING1 polyclonal antibody in PBS containing 5% nonfat milk and 0.1% Tween-20 for 1 h with gentle shaking. The p33
ING1 was then visualized as described .
Statistical analysis
Fisher's exact probability test was performed to estimate the correlation between the expression levels of ING1 mRNA and clinicopathologic factors using the software StatView-J 4.02.
Abbreviations PCR ± SSCP, polymerase chain reaction-single strand conformation polymorphism; RT, reverse transcription; DCIS, ductal carcinoma in situ; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; DAB, 3,3' diaminobenzidine; NBT/BCIP, nitroblue tetrazolium chloride/5-bromo-4-chloro-3-idolyl-phosphate, 4-toluidine salt.
